NCT05136690View on ClinicalTrials.gov

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

September 23, 2022

Study Completion Date

November 4, 2022

Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
DRUG

Nicotine patch

Nicotine 21 mg transdermal nicotine patch.

DRUG

MK-4334

MK-4334 250 mg capsule taken by mouth.

DRUG

Placebo patch

Placebo patch.

DRUG

Placebo capsule

Placebo capsule taken by mouth.

Trial Locations (2)

90806

Collaborative Neuroscience Research, LLC ( Site 0002), Long Beach

08053

Hassman Research Institute Marlton Site ( Site 0001), Marlton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY